📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Chemistry, manufacturing and controls document for TILA-278.
Why it exists. Chemistry, manufacturing, and controls evidence establishing product quality and consistency.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH M4Q / Q6B / Q5
| Field | Value |
|---|---|
| Document ID | M3-S |
| Version | 1.0 |
| Compound | TILA-278 (anti-TL1A antagonist / IL-22R agonist bispecific) |
| Standard | ICH M4Q / Q6B / Q5 |
| Confidentiality | Confidential |
Chemistry, manufacturing and controls document for TILA-278.
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-07-08 | CMC/Quality | Initial issue |
No comments yet. Be the first to say something!
This section describes the drug substance for TILA-278, a recombinant humanized immunoglobulin G1 (IgG1) bispecific monoclonal antibody manufactured by Virtual Biopharma Inc. for the treatment of moderate-to-severe ulcerative colitis (UC). The information is presented in accordance with ICH M4Q(R1) (CTD Quality), ICH Q6B (Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products), ICH Q5A(R2), Q5B, Q5C, Q5D, and ICH Q11. The drug product (a sterile subcutaneous [SC] solution in a single-use prefilled syringe/autoinjector) is described in Module 3.2.P.
Data are reported for the current commercial manufacturing process and for representative development, toxicology, and clinical lots, including the lots used in the pivotal Phase 2b induction study TILA278-201. Numerical entries carrying the discreet marker "" denote representative values pending reconciliation against the corresponding source datasets at final dossier lock.
| Item | Designation |
|---|---|
| Company / development code | TILA-278 (also VBI-278) |
| Proposed INN (WHO) | tilaravimig (proposed; "-mig" stem for a multi-immunoglobulin/bispecific antibody, WHO revised mAb nomenclature scheme) |
| USAN | Pending |
| Chemical/biological class | Recombinant humanized IgG1(κ) bispecific monoclonal antibody, Fc-engineered (effector-attenuated) |
| CAS Registry Number | Pending assignment |
| Antibody format | Asymmetric one-arm-per-target heterodimeric IgG1: knobs-into-holes (KiH) heavy-chain heterodimerization with CrossMab (CH1–CL domain exchange) light-chain pairing |
| Molecular targets | Arm A: human TL1A (TNFSF15) — neutralizing antagonist; Arm B: human IL-22 receptor alpha 1 (IL-22RA1) — agonist |
TILA-278 is a monovalent-per-target (1 + 1) bispecific full-length IgG1 antibody assembled from four distinct polypeptide chains:
Correct heterodimerization is driven by the complementary KiH interface and stabilized by an engineered inter-CH3 disulfide (S354C / Y349C). The LALA-PG Fc abrogates FcγR and C1q binding — appropriate for a molecule intended to neutralize a cytokine and to agonize a receptor rather than to elicit ADCC/CDC — while the native IgG1 FcRn-binding interface is preserved to support the extended half-life required for SC dosing.
Each heavy chain carries a single conserved N-linked glycosylation site at Asn297 (EU numbering) in the CH2 domain. The intra- and inter-chain disulfide connectivity is that of a canonical human IgG1(κ), confirmed by disulfide mapping (Section 3.2.S.3.1). N-terminal heavy-chain glutamine is largely converted to pyroglutamate; C-terminal lysine is variably processed.
Key structural attributes:
| Attribute | Value |
|---|---|
| Number of polypeptide chains | 4 (2 heavy, 2 light; heterodimeric) |
| Deduced (unmodified) polypeptide molecular mass | ~145.8 kDa |
| Observed intact mass (major glycoform, G0F/G0F) | ~148.4 kDa |
| Apparent isoelectric point (pI) | ~8.3 |
| Extinction coefficient ε(0.1%, 280 nm) | 1.52 mL·mg⁻¹·cm⁻¹ |
| N-glycosylation | One site per HC at Asn297 (CH2) |
| Effector-function Fc engineering | L234A / L235A / P329G (LALA-PG) |
| Heterodimerization / pairing engineering | Knobs-into-holes + S354C/Y349C; CrossMab CH1–CL |
TILA-278 drug substance is a clear to slightly opalescent, colourless to slightly yellow aqueous solution. It is highly soluble in the histidine-based formulation buffer and supports the high protein concentration required for a low-volume SC presentation. Higher-order structure (HOS) has been characterized by far- and near-UV circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC); the thermal unfolding profile shows the expected multi-transition IgG1 behaviour with a CH2 transition onset at ~68°C and a dominant Fab/CH3 transition at ~80–83°C. The molecule exhibits pH- and concentration-dependent conformational and colloidal stability consistent with a well-behaved IgG1, with aggregation and fragmentation being the principal degradation pathways under thermal and low-pH stress (Section 3.2.S.7). Biological activity resides in two independent functions: neutralization of TL1A (arm A) and agonism of IL-22RA1 signalling (arm B), both of which are demonstrable on the same molecule (dual-binding; Section 3.2.S.3.1).
The drug substance is manufactured, tested, and released by Virtual Biopharma Inc. (or its named contract manufacturing organization). The name, address, and responsibility of each site involved in manufacture, testing, and batch release are provided in the site table. Valid manufacturing authorizations and GMP compliance status are cross-referenced in Module 1.
TILA-278 is produced by fed-batch mammalian cell culture in a CHO-K1-derived, glutamine-synthetase (GS) selection host cell line, followed by a platform purification train comprising Protein A affinity capture, orthogonal polishing chromatography, dedicated viral inactivation and removal steps, and ultrafiltration/diafiltration (UF/DF) into the final drug-substance buffer. A single production batch is defined as the material derived from one production bioreactor processed through downstream to a single UF/DF pool. Nominal commercial scale is a 2000 L single-use production bioreactor.
Upstream (cell culture):
Downstream (recovery and purification):
Process controls. The control strategy is defined per ICH Q8(R2)/Q11 and comprises critical process parameters (CPPs), key process parameters, in-process controls (IPCs) with proven acceptable ranges, and in-process action/acceptance limits for both product-quality and microbiological attributes. Representative IPCs include viable-cell density and viability, titre, bioburden and endotoxin at defined stages, Protein A eluate pH and inactivation hold time/pH, chromatography pool volumes and product concentrations, aggregate/charge-variant IPCs at polishing pools, integrity testing of the virus-retentive filter, and final UF/DF pool protein concentration and pH. Maximum in-process hold times and storage conditions have been established and validated.
Cell substrate and cell banking. A two-tiered banking system (master cell bank [MCB] and working cell bank [WCB]) has been established, characterized, and tested in accordance with ICH Q5A(R2), Q5B, and Q5D. Testing includes identity (isoenzyme/genetic), viability, sterility, mycoplasma, in vitro and in vivo adventitious virus assays, transmission electron microscopy for retrovirus-like particles, and bovine/porcine virus testing where relevant. Genetic stability and consistency of the coding sequence, copy number, and expression construct have been demonstrated from the MCB through, and beyond, the limit of in vitro cell age (LIVCA) used for production, per ICH Q5B.
Raw materials. Cell-culture media and feeds are chemically defined and animal-component-free. All raw materials of biological origin (where used) comply with TSE/BSE requirements (EMA/410/01 rev. 3; Ph. Eur. 5.2.8), and compendial materials are controlled to Ph. Eur./USP monographs. Compendial and non-compendial raw-material specifications are provided.
Critical steps and their acceptance criteria (e.g., low-pH viral inactivation pH/time, virus-retentive filtration integrity, Protein A and polishing pool acceptance limits, final UF/DF concentration and pH) are defined with justified limits. In-process pool intermediates and their validated hold conditions/times are listed. No isolated, characterized drug-substance intermediate is stored long-term other than the frozen bulk drug substance.
Process performance qualification (PPQ) was executed on consecutive commercial-scale batches, demonstrating consistent process performance and product quality within predefined acceptance criteria. Impurity clearance (HCP, host-cell DNA, Protein A, media components, selection agent/MSX) was demonstrated with adequate margins.
Viral clearance. Viral clearance was evaluated in a scaled-down, qualified model per ICH Q5A(R2) using a panel of relevant and model viruses across the dedicated and contributory steps (low-pH inactivation, AEX, and nanofiltration; with Protein A contribution assessed). Representative cumulative log reduction values (LRV) are summarized below.
| Process step | X-MuLV (enveloped, RNA) | PRV (enveloped, DNA) | MVM/MMV (non-enveloped, DNA) | Reo-3 (non-enveloped, RNA) |
|---|---|---|---|---|
| Low-pH inactivation | ≥ 4.8 | ≥ 4.5 | n/a | n/a |
| AEX (flow-through) | ≥ 4.2 | ≥ 4.0 | ≥ 3.5 | ≥ 4.0 |
| Nanofiltration (20 nm) | ≥ 5.5 | ≥ 5.3 | ≥ 4.8 | ≥ 5.0 |
| Cumulative LRV | ≥ 14.5 | ≥ 13.8 | ≥ 8.3 | ≥ 9.0 |
All values. The orthogonal combination of an enveloped-virus inactivation step (low pH) and two size/charge-based removal steps (AEX, nanofiltration) provides robust clearance of both enveloped and non-enveloped viruses; consistent with parvovirus resistance to low pH, no inactivation credit is claimed for MVM/Reo-3 at the low-pH step. Adventitious-agent control for the process and facility is described in Module 3.2.A.2.
The evolution of the manufacturing process from the early clinical/toxicology process to the commercial process is described, together with comparability assessments per ICH Q5E across process changes and scale-up. The toxicology lots and the clinical lots used in TILA278-201 were manufactured by qualified processes; comparability between clinical and commercial material was demonstrated at the level of physicochemical characterization, both potency assays, and product-/process-related impurity profiles. A quality-by-design summary links CPPs to critical quality attributes (CQAs).
TILA-278 has been extensively characterized using orthogonal, state-of-the-art methods per ICH Q6B, with particular attention to the attributes that are specific to a bispecific IgG1 (correct chain pairing, absence of mispaired/homodimeric species, and independent function of both arms).
Primary structure and post-translational modifications.
Higher-order structure. Far-/near-UV CD and FTIR confirm the expected β-sheet-dominated secondary structure and native tertiary fold; DSC confirms the characteristic multi-transition thermal profile. HOS is comparable between reference standard and process lots.
Glycosylation. Released N-glycan analysis (2-AB labelling, HILIC-UHPLC-FLR with LC-MS confirmation) shows a predominantly core-fucosylated, biantennary complex-type profile dominated by G0F, G1F, and G2F, with minor afucosylated, high-mannose (Man5), and sialylated species; site occupancy at Asn297 is high. Because effector function is engineered out (LALA-PG), afucosylation is not an ADCC-relevant CQA but is monitored for consistency; high-mannose content is monitored for its potential effect on clearance.
Charge and size heterogeneity.
Biological characterization — both binding functions.
Product-related substances and impurities.
Process-related impurities.
| Impurity | Method | Typical level in DS |
|---|---|---|
| Host-cell protein (HCP) | Anti-CHO HCP ELISA | ≤ 100 ppm |
| Residual host-cell DNA | CHO-specific qPCR | ≤ 100 pg/mg |
| Residual Protein A (leached ligand) | ELISA | ≤ 20 ng/mg |
| Residual selection agent (MSX) / media components | LC-MS/MS or specific assay | Below action limit; cleared |
Impurity clearance across the purification train has been demonstrated with adequate margins (Section 3.2.S.2.5), and the clinically qualified levels are reflected in the specification (Section 3.2.S.4).
The drug-substance specification (ICH Q6B) comprises identity, quantity, purity/impurities, potency (both functions), and safety attributes. Representative acceptance criteria are shown below; individual numerical limits marked "" will be finalized as additional commercial manufacturing data accrue.
| Attribute | Test / method | Acceptance criterion |
|---|---|---|
| Appearance | Visual (Ph. Eur. 2.2.1/2.2.2) | Clear to slightly opalescent, colourless to slightly yellow liquid, essentially free from visible particles |
| pH | Potentiometry (Ph. Eur. 2.2.3) | 5.5 ± 0.3 |
| Protein concentration | UV absorbance at 280 nm | 100 ± 10 mg/mL |
| Identity — anti-TL1A arm | Peptide map / target-binding identity | Conforms to reference standard |
| Identity — IL-22RA1 arm | Target-binding identity | Conforms to reference standard |
| Charge-variant identity/profile | icIEF | Comparable to reference standard |
| Purity — size (aggregates) | SE-HPLC | Monomer ≥ 95.0%; HMW ≤ 3.0%; LMW ≤ 2.0% |
| Purity — non-reduced | CE-SDS (non-reduced) | Main (intact bispecific) ≥ 90.0% |
| Purity — reduced | CE-SDS (reduced) | Sum of HC + LC ≥ 95.0% |
| Charge variants | icIEF | Main 55–75%; acidic ≤ 30%; basic ≤ 15% |
| Glycosylation | Released N-glycan (2-AB HILIC) | High-mannose (Man5) ≤ 8%; report G0F/G1F/G2F |
| Potency — TL1A neutralization | Cell-based reporter (relative potency) | 80–125% of reference standard |
| Potency — IL-22RA1 agonism | Cell-based STAT3 reporter (relative potency) | 70–130% of reference standard |
| HCP | Anti-CHO HCP ELISA | ≤ 100 ppm |
| Residual host-cell DNA | CHO-specific qPCR | ≤ 100 pg/mg |
| Residual Protein A | ELISA | ≤ 20 ng/mg |
| Bacterial endotoxin | LAL, kinetic chromogenic (Ph. Eur. 2.6.14 / USP <85>) | ≤ 0.5 EU/mg |
| Bioburden | Ph. Eur. 2.6.12 / USP <61> | ≤ 1 CFU/10 mL |
Non-compendial methods (SE-HPLC, CE-SDS reduced/non-reduced, icIEF, peptide-map/binding identity, released N-glycan analysis, both cell-based potency assays, HCP ELISA, host-cell DNA qPCR, Protein A ELISA, UV concentration) are described with sufficient detail to permit execution (system suitability, reference/control standards, calculation of relative potency by parallel-line/four-parameter logistic analysis). Compendial methods (appearance, pH, endotoxin, bioburden) are performed per the referenced Ph. Eur./USP chapters. The two potency assays independently interrogate the two mechanisms of action of the molecule (TL1A antagonism and IL-22RA1 agonism), consistent with the complementary anti-inflammatory and mucosal-healing rationale of the programme.
All non-compendial release methods have been validated in accordance with ICH Q2(R2) for the relevant characteristics (specificity, accuracy, precision [repeatability and intermediate precision], linearity, range, and for potency, relative accuracy and dilutional linearity). Compendial methods have been verified for use with TILA-278. Validation summaries and acceptance criteria are provided.
Batch-analysis data are provided for development, toxicology, and clinical drug-substance lots, including the lots used to manufacture drug product for the pivotal Phase 2b study TILA278-201. Representative results are summarized below (all values).
| Attribute | DS-278-0002 (Tox lot) | DS-278-0005 (Clinical, TILA278-201) | DS-278-0006 (Clinical, TILA278-201) | DS-278-0011 (PPQ) |
|---|---|---|---|---|
| Concentration (mg/mL) | 101 | 99 | 102 | 100 |
| pH | 5.5 | 5.5 | 5.4 | 5.5 |
| SEC monomer (%) | 98.6 | 98.4 | 98.5 | 98.7 |
| SEC HMW (%) | 1.1 | 1.3 | 1.2 | 1.0 |
| CE-SDS non-reduced main (%) | 93.8 | 93.1 | 93.5 | 94.0 |
| icIEF main (%) | 66 | 64 | 65 | 67 |
| TL1A neutralization (% RS) | 104 | 98 | 101 | 100 |
| IL-22RA1 agonism (% RS) | 96 | 93 | 97 | 99 |
| HCP (ppm) | 28 | 41 | 37 | 22 |
| Residual DNA (pg/mg) | < 10 | < 10 | < 10 | < 10 |
| Endotoxin (EU/mg) | < 0.1 | < 0.1 | < 0.1 | < 0.1 |
Results across lots are consistent and within the proposed acceptance criteria, supporting process consistency and comparability of the clinically qualified material.
The specification is justified per ICH Q6B on the basis of: (i) the characterization data (Section 3.2.S.3); (ii) the clinically and non-clinically qualified ranges observed in the toxicology lots and the TILA278-201 clinical lots; (iii) manufacturing capability and process consistency (PPQ and batch analyses); (iv) stability behaviour (Section 3.2.S.7); and (v) assay capability. Two orthogonal potency assays are included because both binding functions are essential to the mechanism of action; purity, charge, size, and impurity limits are set to control the CQAs identified in the QbD assessment. Acceptance criteria will be tightened as additional commercial manufacturing experience accrues.
A two-tiered reference-standard system is used. The primary reference standard (PRS) was established from a well-characterized, representative clinical-quality lot and fully characterized by the orthogonal panel in Section 3.2.S.3. Working reference standards (WRS) are qualified against the PRS using a predefined protocol (identity, potency for both functions, purity, and charge/size profile) and used for routine release and stability potency determinations. The qualification and requalification protocols, storage conditions (≤ −70°C), and traceability of the current standards to the PRS are documented. The reference standard is used to report both potency assays as relative potency.
The drug substance is filled into sterile, single-use bioprocess containers (fluoropolymer/ethylene-vinyl-acetate multilayer bags with appropriate tubing/connectors, or PETG bottles) and stored frozen at ≤ −40°C. Product-contact materials comply with the relevant compendial requirements for plastic containers for pharmaceutical use (Ph. Eur. 3.1.x; USP <87>/<88> biological reactivity, Class VI) and food-contact regulations. Container-closure integrity and suitability (protection, compatibility, and safety) have been demonstrated, and an extractables/leachables assessment appropriate to a frozen protein drug substance has been performed. The maximum frozen storage duration and permitted freeze/thaw cycles are defined and supported by stability data (Section 3.2.S.7).
Stability of the drug substance has been evaluated under ICH Q5C and Q1A(R2) conditions using stability-indicating methods (SE-HPLC, CE-SDS, icIEF, both potency assays, appearance, pH, protein concentration, and sub-visible particles). Studies include long-term storage at the intended condition (≤ −40°C), accelerated (5 ± 3°C), and stressed/thermal (25 ± 2°C and 40 ± 2°C) conditions, together with freeze–thaw cycling and forced-degradation and photostability (ICH Q1B) studies to demonstrate method specificity and to characterize degradation pathways.
Under the intended frozen storage condition, TILA-278 drug substance is stable, with all attributes remaining within acceptance criteria for the full duration tested. The principal degradation pathways observed under accelerated/stressed conditions are aggregation (increase in SEC HMW), fragmentation (CE-SDS), and charge-variant shifts (increase in acidic species, reflecting deamidation), accompanied by gradual loss of relative potency at thermal-stress conditions; both potency assays track molecular integrity. No unexpected degradants were observed. Freeze–thaw cycling within the defined number of cycles produced no meaningful change.
Based on the available long-term data at ≤ −40°C and supported by accelerated/stressed data, a drug-substance shelf life of 36 months at ≤ −40°C is proposed.
| Condition | Attributes monitored | Outcome |
|---|---|---|
| ≤ −40°C (long-term) | Full panel | Within acceptance criteria through last time point tested |
| 5 ± 3°C (accelerated) | Full panel | Minor increase in aggregate/acidic species; within criteria over tested interval |
| 25 °C / 40 °C (stressed) | Stability-indicating panel | Aggregation, fragmentation, charge shift and potency loss — confirms method specificity |
| Freeze–thaw | SEC, CE-SDS, potency, particles | No significant change within defined cycle limit |
| Photostability (ICH Q1B) | Full panel | Sensitive to light; protect from light |
Virtual Biopharma Inc. commits to: (i) continue long-term stability testing of the primary batches through the full proposed shelf life; and (ii) place the first commercial-scale batches on the post-approval long-term stability protocol, testing at the defined intervals using the methods and acceptance criteria above. Any confirmed out-of-specification or significant adverse trend will be reported to the health authority per regional requirements.
Detailed stability data tables for all primary and supporting batches (including the toxicology and TILA278-201 clinical lots) are provided, with tabulated and graphical presentation of each attribute versus time and statistical evaluation of the long-term data supporting the proposed shelf life.
Cross-references: adventitious-agent safety (3.2.A.2); manufacturing facilities (3.2.A.1); excipients and drug-product formulation, container-closure, and stability for the SC prefilled syringe/autoinjector (3.2.P); regional information (3.2.R).